CN115645631A - Eluting stent based on ginsenoside composite coating - Google Patents
Eluting stent based on ginsenoside composite coating Download PDFInfo
- Publication number
- CN115645631A CN115645631A CN202211463381.8A CN202211463381A CN115645631A CN 115645631 A CN115645631 A CN 115645631A CN 202211463381 A CN202211463381 A CN 202211463381A CN 115645631 A CN115645631 A CN 115645631A
- Authority
- CN
- China
- Prior art keywords
- drug
- spinning solution
- ginsenoside
- spinning
- elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to the technical field of medical treatment, in particular to an elution bracket based on a ginsenoside composite coating, which comprises an elution metal bracket and a drug-loaded layer arranged on the outer side of the elution bracket; the drug-carrying layer is mainly prepared from paclitaxel, chitosan, antithrombotic drug and polyacrylate. The preparation method of the drug-loaded layer comprises the following steps: a first spinning solution consisting of paclitaxel, chitosan and polyacrylate; a second spinning solution consisting of ginsenoside Rg3 and polyacrylate; and (3) mutually interweaving the first spinning solution and the second spinning solution on the outer side of the metal support through a double-end electrostatic spinning machine to spin an electrostatic spinning layer, uniformly spraying an antithrombotic drug solution after the first spinning solution is spun, and continuing to spin the second spinning solution to prepare the drug-loaded layer. The invention arranges various medicines on the medicine-carrying layer in the best compatibility state by the way of electrostatic spinning interweaving on the medicine-carrying layer, so that the medicine can exert better medicine effect in the releasing process.
Description
Technical Field
The invention relates to the technical field of medical treatment, in particular to an elution bracket based on a ginsenoside composite coating.
Background
The Drug Eluting Stent (DES) is a stent which uses a bare metal stent platform to carry (carry) drugs for resisting the intimal hyperplasia of blood vessels, and the drugs are eluted and released locally in the blood vessels to effectively inhibit the intimal hyperplasia of the stent so as to prevent restenosis in the stent. The effective use of drug eluting stents can greatly reduce the incidence of restenosis and re-interventional procedures, but does not reduce the mortality rate.
At present, the polymers of drug eluting stents cause inflammation of the tissue during degradation and may cause thrombosis. In the prior art, antithrombotic drugs such as antithrombotic drugs and the like are added on the drug-loaded layer, but when the drug-loaded layer contains more than one drug component, the problem of high and low drug release speed is involved, so that the effect of the drugs is influenced.
Disclosure of Invention
Technical problem to be solved
In view of the above disadvantages and shortcomings of the prior art, the present invention provides an elution stent based on a ginsenoside composite coating, wherein various drugs are arranged on a drug-loaded layer in an optimal compatibility state by an electrostatic spinning interweaving manner on the drug-loaded layer, so that the drug-loaded layer can exert better drug effect in a release process.
(II) technical scheme
In order to achieve the purpose, the invention adopts the main technical scheme that:
the invention provides an elution bracket based on a ginsenoside composite coating, which comprises an elution metal bracket and a drug-loaded layer arranged on the outer side of the elution bracket;
the drug-carrying layer is mainly prepared from paclitaxel, chitosan, antithrombotic drugs and polyacrylate.
The preparation method of the drug-loaded layer comprises the following steps:
a first spinning solution consisting of paclitaxel, chitosan and polyacrylate;
a second spinning solution consisting of ginsenoside Rg3 and polyacrylate;
and (3) mutually interweaving the first spinning solution and the second spinning solution on the outer side of the metal support through a double-end electrostatic spinning machine to spin an electrostatic spinning layer, uniformly spraying an antithrombotic drug solution after the first spinning solution is spun, and continuing spinning the second spinning solution to prepare a drug-loaded layer.
Wherein the polyacrylate can be dissolved in tetrahydrofuran to obtain solution, and then paclitaxel and chitosan are dissolved therein. The chitosan and the polyacrylate play a role in crosslinking and curing, and the chitosan can relieve the damage of other high molecular polymers to the organism.
The anti-thrombotic drug solution may be a heparin solution.
Optionally, the mass concentrations of paclitaxel and chitosan in the first spinning solution are 0.5-1.2% and 30-40%, respectively.
Optionally, the mass concentration of the ginsenoside Rg3 in the second spinning solution is 40-50%.
Optionally, the spinning weight ratio of the first spinning solution to the second spinning solution is 1: 2 to 4.
Optionally, the weight of the sprayed antithrombotic drug liquid is 10 to 20% of the first spinning solution.
Optionally, the eluting stent is a vascular drug eluting stent.
(III) advantageous effects
The invention has the beneficial effects that:
the invention arranges various medicines on the medicine-carrying layer in the best compatibility state by the way of electrostatic spinning interweaving on the medicine-carrying layer, so that the medicines can exert better medicine effect in the releasing process;
wherein, the ginsenoside can realize good ISR resistance, cardiovascular and cerebrovascular protection, anti-inflammation and anti-infection effects; the paclitaxel and the ginsenoside form a tiny network structure in an electrostatic spinning interweaving mode, so that the paclitaxel and the ginsenoside have the same chance to be exposed on the drug-carrying layer and can be simultaneously and uniformly released, the anti-restenosis effect is exerted, the obvious synergistic effect is exerted, the antithrombotic drug is exposed at the micropore part of the network structure and is released together with other drug components, and the drugs are prevented from being mixed together to form the drug-carrying layer to interact, so that the drug effect is influenced.
Detailed Description
For a better understanding of the present invention, reference will now be made in detail to the present invention by way of specific embodiments thereof.
Example 1
In the intravascular stent provided by the embodiment, the drug-loaded layer is arranged on the outer side of the metal stent;
the preparation method comprises the following steps:
s1, dissolving polyacrylate in tetrahydrofuran in advance to prepare a solution with the concentration of 30%, dissolving paclitaxel and chitosan in the solution to make the mass concentrations of the paclitaxel and the chitosan respectively be 1% and 36%, and preparing a first spinning solution;
s2, dissolving polyacrylate in tetrahydrofuran in advance to prepare a solution with the concentration of 30%, dissolving ginsenoside Rg3 in the solution to ensure that the mass concentration of the ginsenoside Rg3 is 45%, and preparing a second spinning solution;
s3, mutually interweaving the spinning in the first spinning solution and the spinning in the second spinning solution at the weight ratio of 1: 3 on the outer side of the metal bracket through a double-end electrostatic spinning machine to spin an electrostatic spinning layer,
after the first spinning solution finishes spinning, heparin solution is uniformly sprayed, spinning of the second spinning solution is continued to prepare a drug-loaded layer, and the drug content of heparin in the drug-loaded layer is 0.8 mu g/mm.
The drug release result of the embodiment shows that the heparin is regularly and stably released for 52.8 percent in 30 days, and is completely released in 60 days;
regularly and stably releasing 63.5 percent of paclitaxel in 30 days, and completely releasing the paclitaxel in 70 days;
the ginsenoside Rg3 is regularly and stably released within 30 days to reach 71.8 percent, and is completely released within 50 days;
this example was tested to yield:
dissolving polyacrylate in tetrahydrofuran to obtain 30% solution, dissolving heparin, paclitaxel and ginsenoside Rg3, and spraying on the outer side of the metal stent to obtain a drug-carrying layer.
The experiment shows that the heparin is regularly and stably released for 61.3 percent in 30 days, and is completely released in 50 days;
paclitaxel is regularly and stably released for 55 percent in 30 days, and is completely released in 65 days;
the ginsenoside Rg3 is regularly and stably released for 66.4 percent within 30 days, and is completely released within 50 days.
As can be seen from the above, the release time and the examples are not significantly different, but the effect of mixing different drug components together can be overcome.
Example 2
In the intravascular stent provided by the embodiment, the drug-loaded layer is arranged on the outer side of the metal stent;
the preparation method comprises the following steps:
s1, dissolving polyacrylate in tetrahydrofuran in advance to prepare a solution with the concentration of 30%, dissolving paclitaxel and chitosan in the solution to make the mass concentrations of the paclitaxel and the chitosan respectively be 1.2% and 40%, and preparing a first spinning solution;
s2, dissolving polyacrylate in tetrahydrofuran in advance to prepare a solution with the concentration of 30%, dissolving ginsenoside Rg3 in the solution to enable the mass concentration of the ginsenoside Rg3 to be 50%, and preparing a second spinning solution;
s3, mutually interweaving the spinning in the first spinning solution and the second spinning solution at a weight ratio of 1: 4 through a double-end electrostatic spinning machine to spin an electrostatic spinning layer on the outer side of the metal bracket,
after the first spinning solution finishes spinning, evenly spraying heparin solution, and then continuing spinning the second spinning solution to prepare a drug-loaded layer, wherein the drug content of heparin in the drug-loaded layer is 1 microgram/mm.
Example 3
In the intravascular stent provided by the embodiment, the drug-loaded layer is arranged on the outer side of the metal stent;
the preparation method comprises the following steps:
s1, dissolving polyacrylate in tetrahydrofuran in advance to prepare a solution with the concentration of 30%, dissolving paclitaxel and chitosan in the solution to make the mass concentrations of the paclitaxel and the chitosan respectively be 0.5% and 30%, and preparing a first spinning solution;
s2, dissolving polyacrylate in tetrahydrofuran in advance to prepare a solution with the concentration of 30%, dissolving ginsenoside Rg3 in the solution to enable the mass concentration of the ginsenoside Rg3 to be 40%, and preparing a second spinning solution;
s3, mutually interweaving the spinning in the first spinning solution and the spinning in the second spinning solution at the weight ratio of 1: 2 on the outer side of the metal bracket through a double-end electrostatic spinning machine to spin an electrostatic spinning layer,
after the first spinning solution finishes spinning, evenly spraying heparin solution, and then continuing the spinning of the second spinning solution to prepare a drug-loaded layer, wherein the drug content of heparin in the drug-loaded layer is 0.7 mu g/mm
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and these modifications or substitutions do not depart from the spirit of the corresponding technical solutions of the embodiments of the present invention.
Claims (7)
1. An elution bracket based on a ginsenoside composite coating is characterized by comprising an elution metal bracket and a drug-loaded layer arranged on the outer side of the elution bracket;
the drug-carrying layer is mainly prepared from paclitaxel, chitosan, antithrombotic drugs and polyacrylate.
2. The elution stent based on ginsenoside composite coating of claim 1, wherein the preparation method of the drug-loaded layer comprises the following steps:
a first spinning solution consisting of paclitaxel, chitosan and polyacrylate;
a second spinning solution consisting of ginsenoside Rg3 and polyacrylate;
and (3) mutually interweaving the first spinning solution and the second spinning solution on the outer side of the metal support through a double-end electrostatic spinning machine to spin an electrostatic spinning layer, uniformly spraying an antithrombotic drug solution after the first spinning solution is spun, and continuing spinning the second spinning solution to prepare a drug-loaded layer.
3. An eluting stent based on ginsenoside composite coatings according to claim 1, wherein: the mass concentrations of the paclitaxel and the chitosan in the first spinning solution are 0.5-1.2% and 30-40% respectively.
4. An eluting stent based on ginsenoside composite coatings according to claim 1, wherein: the mass concentration of the ginsenoside Rg in the second spinning solution is 40-50%.
5. An eluting stent based on ginsenoside composite coating in claim 1, wherein: the spinning weight ratio of the first spinning solution to the second spinning solution is 1: 2 to 4.
6. An eluting stent based on ginsenoside composite coating in claim 1, wherein: the weight of the sprayed antithrombotic drug liquid is 10 to 20 percent of that of the first spinning solution.
7. An elution stent vascular drug elution stent based on a ginsenoside composite coating according to any one of claims 1 to 6, which is characterized in that: the elution bracket is a blood vessel medicine elution bracket.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211463381.8A CN115645631A (en) | 2022-11-22 | 2022-11-22 | Eluting stent based on ginsenoside composite coating |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211463381.8A CN115645631A (en) | 2022-11-22 | 2022-11-22 | Eluting stent based on ginsenoside composite coating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115645631A true CN115645631A (en) | 2023-01-31 |
Family
ID=85017116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211463381.8A Pending CN115645631A (en) | 2022-11-22 | 2022-11-22 | Eluting stent based on ginsenoside composite coating |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115645631A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013015495A1 (en) * | 2011-07-27 | 2013-01-31 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구 | Non-vascular drug-eluting stent membrane using electrospinning, and method for manufacturing same |
| CN103599090A (en) * | 2013-07-30 | 2014-02-26 | 江南大学 | Multi-layer drug sustain-release nano fiber membrane and preparation method thereof |
| US20140086971A1 (en) * | 2012-09-21 | 2014-03-27 | Merit Medical Systems, Inc. | Drug-eluting rotational spun coatings and methods of use |
| US20150030688A1 (en) * | 2013-07-25 | 2015-01-29 | Saint Louis University | Honey and growth factor eluting scaffold for wound healing and tissue engineering |
| CN106668049A (en) * | 2016-12-29 | 2017-05-17 | 创领心律管理医疗器械（上海）有限公司 | Anti-microbial component and preparation method thereof |
-
2022
- 2022-11-22 CN CN202211463381.8A patent/CN115645631A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013015495A1 (en) * | 2011-07-27 | 2013-01-31 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구 | Non-vascular drug-eluting stent membrane using electrospinning, and method for manufacturing same |
| US20140086971A1 (en) * | 2012-09-21 | 2014-03-27 | Merit Medical Systems, Inc. | Drug-eluting rotational spun coatings and methods of use |
| US20150030688A1 (en) * | 2013-07-25 | 2015-01-29 | Saint Louis University | Honey and growth factor eluting scaffold for wound healing and tissue engineering |
| CN103599090A (en) * | 2013-07-30 | 2014-02-26 | 江南大学 | Multi-layer drug sustain-release nano fiber membrane and preparation method thereof |
| CN106668049A (en) * | 2016-12-29 | 2017-05-17 | 创领心律管理医疗器械（上海）有限公司 | Anti-microbial component and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 魏长志 等主编: "天然生物活性物质及其制备技术", 河南科学技术出版社, pages: 171 - 117 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7438925B2 (en) | Drug eluting coatings for medical implants | |
| CN104511084A (en) | Balloon catheter | |
| US20060204537A1 (en) | Silicone blends and composites for drug delivery | |
| JP2010540199A (en) | Diarsenic trioxide drug-eluting stent | |
| CN106334220B (en) | The coating processes of medication coat on medical instrument | |
| CN107496996B (en) | Drug-loaded intravascular stent and preparation method thereof | |
| CN101703428B (en) | Intravascular scaffold provided with anti-restenosis coating layer and preparation method thereof | |
| CN114246992B (en) | Degradable intravascular stent with slow-release drug coating and preparation method thereof | |
| KR100455343B1 (en) | Covering composition for drug releasing stent and drug releasing stent manufactured using same | |
| CN107376030A (en) | A kind of preparation method of medicinal balloon, the medicinal balloon being prepared and its application | |
| CN109172876A (en) | It is a kind of to ease up the newtype drug bracket of Slow release coating simultaneous with rapid delivery of pharmaceuticals | |
| CN115645631A (en) | Eluting stent based on ginsenoside composite coating | |
| CN104174073A (en) | Method for loading drugs on drug eluting balloon catheter | |
| CN103536971A (en) | Drug eluting medical appliance capable of controllably releasing drugs and preparation method thereof | |
| CN102018996A (en) | Manufacturing method of drug vessel support with antibody immobilized on surface of support | |
| JP5597625B2 (en) | Drug eluting stent | |
| An et al. | Construction and evaluation of nitric oxide generating vascular graft material loaded with organoselenium catalyst via layer-by-layer self-assembly | |
| CN115137879B (en) | Blood contact material for resisting coagulation and promoting vascular repair and preparation method thereof | |
| CN108338989B (en) | Compound anti-restenosis medicine of coronary artery medicine elution bracket and controlled release system thereof | |
| CN112535767A (en) | Preparation method of fallopian tube scaffold | |
| CN112691237A (en) | Medicine-coated plastic capsule and preparation method thereof | |
| US20200254152A1 (en) | Coating system for medical devices | |
| EP3226925B1 (en) | Drug eluting device | |
| CN115337467A (en) | Drug coating, intravascular stent, and preparation method and application thereof | |
| CN107737382A (en) | A kind of spraying method of blood vessel stent drug coating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |